.png)
Sindroma Koroner Akut pada Pasien Kanker: Pendekatan Manajemen Kardio-Onkologi
Abstract
Kanker dan penyakit jantung koroner saling berhubungan karena memiliki faktor risiko yang sama, dimana pasien kanker akan memiliki risiko lebih tinggi terkena penyakit jantung koroner dan serangan jantung atau sindroma koroner akut. Selain itu, terapi kanker baik obat-obatan, kemoterapi atau radioterapi dapat menyumbang patofisiologi terjadinya sindroma koroner akut. Gejala klinis nya pun bervariasi dan tidak khas, sehingga diperlukan penegakan diagnosis menggunakan pemeriksaan penunjang lainnya. Manajemen sindroma koroner akut pada pasien kanker sesuai dengan pendekatan kardio-onkologi, berupa evaluasi risiko trombosis atau perdarahan, stadium atau jenis kanker, penyulit anemia, angka harapan hidup dan prognosis. Hal inilah yang menyebabkan tatalaksana sindroma koroner akut (SKA) pada pasien kanker sangatlah tergantung kondisi pasien tersebut.
Kata kunci: kanker, sindroma koroner akut, tatalaksana
Full Text:
PDF (Bahasa Indonesia)References
Koene RJ, Prizment AE, Blaes A, et al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016; 133(11): 1104–1114,
Costa IBSDS, Andrade FTA, Carter D, Seleme VB, Costa MS, Campos CM, Hajjar LA. Challenges and Management of Acute Coronary Syndrome in Cancer Patients. Front Cardiovasc Med. 2021;8:590016.
Mamas MA, Brown SA, Sun LY. Coronary artery disease in patients with cancer: It’s always the small pieces that make the bigger picture. Mayo Clin Proc. 2020; 95(9): 1819–1821.
Wang Z, Fan Z, Yang L, et al. Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors. Front Cardiovasc Med. 2023; 10: 1014400, doi: 10.3389/fcvm.2023.1014400, indexed in Pubmed: 36760569.
Bisceglia I., Canale M.L., Lestuzzi C., Parrini I., Russo G., Colivicchi F., Gabrielli D., Gulizia M.M., Iliescu C.A. Acute coronary syndromes in cancer patients. J. Cardiovasc. Med. 2020;21:944–952
Radmilovic J., Di Vilio A., D’Andrea A., Pastore F., Forni A., Desiderio A., Ragni M., Quaranta G., Cimmino G., Russo V., et al. The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome. J. Clin. Med. 2020;9:3926.
Bharadwaj A., Potts J., Mohamed M.O., Parwani P., Swamy P., Lopez-Mattei J.C., Rashid M., Kwok C.S., Fischman D.L., Vassiliou V.S., et al. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur. Heart J. 2020;41:2183–2193.
Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Elkind M.S.V., Panageas K.S., DeAngelis L.M. Risk of Arterial Thromboembolism in Patients with Cancer. J. Am. Coll. Cardiol. 2017;70:926–938.
Kanduri J., More L.A., Godishala A., Asnani A. Fluoropyrimidine-Associated Cardiotoxicity. Cardiol. Clin. 2019;37:399–405.
Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Tagawa S.T., Panageas K.S., DeAngelis L.M. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133:781–789.
Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020; 22(11): 1945–1960
Touyz R.M., Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. npj Precis. Oncol. 2018;2:13.
Potts JE, Iliescu CA, Lopez Mattei JC, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J. 2019; 40(22): 1790–1800
Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Elkind M.S.V., Panageas K.S., DeAngelis L.M. Risk of Arterial Thromboembolism in Patients with Cancer. J. Am. Coll. Cardiol. 2017;70:926–938.
Herrmann J., Yang E.H., Iliescu C.A., Cilingiroglu M., Charitakis K., Hakeem A., Toutouzas K., Leesar M.A., Grines C.L., Marmagkiolis K. Vascular Toxicities of Cancer Therapies: The Old and the New—An Evolving Avenue. Circulation. 2016;133:1272–1289.
Lyon A.R., Yousaf N., Battisti N.M.L., Moslehi J., Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19:e447–e458.
Al-Hawwas M., Tsitlakidou D., Gupta N., Iliescu C., Cilingiroglu M., Marmagkiolis K. Acute Coronary Syndrome Management in Cancer Patients: “Good News” in Cancer Patients? Curr. Oncol. Rep. 2018;20:78.
Rohrmann S., Witassek F., Erne P., Rickli H., Radovanovic D. Treatment of patients with myocardial infarction depends on history of cancer. Eur. Heart J. Acute Cardiovasc. Care. 2017;7:639–645.
Guddati A.K., Joy P.S., Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J. Cancer Res. Clin. Oncol. 2015;142:471–479.
Lenneman C.G., Sawyer D.B. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circ. Res. 2016;118:1008–1020.
Munoz E., Iliescu G., Vejpongsa P., Charitakis K., Karimzad K., Lopez-Mattei J., Yusuf S.W., Marmagkiolis K., Iliescu C. Takotsubo Stress Cardiomyopathy. J. Am. Coll. Cardiol. 2016;68:1143–1144.
Doolub G, Mamas MA. Percutaneous coronary angioplasty in patients with cancer: Clinical challenges and management strategies. J Pers Med. 2022; 12(9): 1372
Collet J.-P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L., Dendale P., Dorobantu M., Edvardsen T., Folliguet T., et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2021;42:1289–1367.
Yadav M, Généreux P, Giustino G, et al. Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute coronary syndromes who undergo percutaneous coronary intervention. Can J Cardiol. 2016; 32(2): 226–233
Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: A review. Ann Palliat Med. 2018; 7(2): 265–273
Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019; 40(31): 2632–2653
Raposeiras-Roubín S, Abu-Assi E, Muñoz-Pousa I, et al. Usefulness of bleeding after acute coronary syndromes for unmasking silent cancer. Am J Cardiol. 2020; 125(12): 1801–1808
Kirresh A, White L, Mitchell A, et al. Radiation-induced coronary artery disease: a difficult clinical conundrum. Clin Med (Lond). 2022; 22(3): 251–256
Ferrante G, Rao SV, Jüni P, et al. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials. JACC Cardiovasc Interv. 2016; 9(14): 1419–1434.
Gargiulo G, Giacoppo D, Jolly SS, et al. Effects on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: meta-analysis of individual patient data from 7 multicenter randomized clinical trials. Circulation. 2022; 146(18): 1329–1343.
Valgimigli M, Saia F, Guastaroba P, et al. Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell’Emilia-Romagna) multicenter registry. JACC Cardiovasc Interv. 2012; 5(1): 23–35.
Seto AH, Roberts JS, Abu-Fadel MS, et al. Real-time ultrasound guidance facilitates transradial access: RAUST (Radial Artery access with Ultrasound Trial). JACC Cardiovasc Interv. 2015; 8(2): 283–291.
Madder RD, Seth M, Sukul D, et al. Rates of intracoronary imaging optimization in contemporary percutaneous coronary intervention: a report from the BMC2 registry. Circ Cardiovasc Interv. 2022; 15(10): e012182.
Leong DP, Cirne F, Aghel N, Baro Vila RC, Cavalli GD, Ellis PM, Healey JS, Whitlock R, Khalaf D, Mian H, Jolly SS, Mehta SR, Dent S. Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: State-of-the-Art Review. JACC CardioOncol. 2023;5(4):415-430.
de la Torre Hernandez JM, Hernandez FH, Alfonso F, et al. Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions. J Am Coll Cardiol. 2011; 58(4): 351–358.
Iliescu CA, Cilingiroglu M, Giza DE, et al. „Bringing on the light” in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J. 2017; 194: 83–91.
DOI: https://doi.org/10.30596/amj.v8i1.21637
DOI (PDF (Bahasa Indonesia)): https://doi.org/10.30596/amj.v8i1.21637.g12714
Refbacks
- There are currently no refbacks.
Jurnal Kedokteran Anatomica/ Anatomica Medical Journal (AMJ)
E-mail: amj_fk@umsu.ac.id || Editorial Contact: 081375150018
This work is licensed under aCreative Commons Attribution-ShareAlike 4.0 International License.